This company has been marked as potentially delisted and may not be actively trading. NASDAQ:XOMA XOMA Royalty (XOMA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsInsider TradesNews and TrendsOwnershipShort Interest About XOMA Royalty Stock (NASDAQ:XOMA) Get XOMA Royalty alerts:Sign Up Key Stats Today's Range$40.17▼$40.1750-Day Range$39.36▼$45.0052-Week Range$22.29▼$45.22VolumeN/AAverage Volume497,905 shsMarket Capitalization$503.77 millionP/E Ratio25.59Dividend YieldN/APrice Target$53.75Consensus RatingHold Company Overview XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders. The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways. Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.AI Generated. May Contain Errors. Read More Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA Royalty and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMA Stock News HeadlinesLGND: XOMA Acquisition ClosedAugust 10, 2026 | finance.yahoo.comLigand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On EarningsJuly 17, 2026 | finance.yahoo.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 27 at 1:00 AM | Banyan Hill Publishing (Ad)Ligand Pharma completes transformative XOMA royalty acquisitionJuly 15, 2026 | tipranks.comXOMA Royalty Corporation Completes Merger with Ligand PharmaceuticalsJuly 15, 2026 | tipranks.comAnalyst Raises Ligand Price Target to $388 on XOMA-Driven Growth Outlook and Enhanced Royalty PortfolioJuly 9, 2026 | tipranks.comXOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash AcquisitionJune 27, 2026 | finance.yahoo.comXOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash AcquisitionJune 27, 2026 | finance.yahoo.comSee More Headlines XOMA Stock Analysis - Frequently Asked Questions How were XOMA Royalty's earnings last quarter? XOMA Royalty Corporation (NASDAQ:XOMA) issued its quarterly earnings results on Tuesday, May, 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by $0.02. The biotechnology company had revenue of $12.32 million for the quarter, compared to analysts' expectations of $13.91 million. XOMA Royalty had a trailing twelve-month return on equity of 12.56% and a net margin of 53.46%. Who are XOMA Royalty's major shareholders? Top institutional investors of XOMA Royalty include Newtyn Management LLC (5.66%), Opaleye Management Inc. (2.70%), Bank of New York Mellon Corp (0.60%) and California State Teachers Retirement System. Insiders that own company stock include Bvf Partners L P/Il, Owen Hughes, Thomas M Burns, Joseph M Limber and Bradley Sitko. View institutional ownership trends. What other stocks do shareholders of XOMA Royalty own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/12/2026Today9/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 XOMA's financial health is in the Green zone, according to TradeSmith. XOMA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Price Target for XOMA Royalty$53.75 High Price Target$76.00 Low Price Target$39.00 Potential Upside/Downside+33.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$1.57 Trailing P/E Ratio25.59 Forward P/E Ratio44.63 P/E GrowthN/ANet Income$31.71 million Net Margins53.46% Pretax Margin69.85% Return on Equity12.56% Return on Assets4.11% Debt Debt-to-Equity Ratio0.96 Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual Sales$7.65 million Price / Sales65.83 Cash Flow$0.57 per share Price / Cash Flow70.46 Book Value$6.77 per share Price / Book5.93Miscellaneous Outstanding Shares12,541,000Free Float11,425,000Market Cap$503.77 million OptionableOptionable Beta0.86 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:XOMA) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
